NaPro Announces the Sale of Two Million Common Shares
26 Marzo 2004 - 2:00PM
PR Newswire (US)
NaPro Announces the Sale of Two Million Common Shares BOULDER,
Colo., March 26 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics,
Inc. today announced that it has entered into a transaction with
two institutional investors for the purchase of an aggregate of 2
million common shares at $2.60 per share in an offering made from
its currently effective shelf registration. "The net proceeds of
this investment will help support the continued development of our
new product pipeline and provide additionalfunding for selected
strategic in-licensing opportunities that may arise," commented
Leonard P. Shaykin, Chairman and Chief Executive Officer. About
NaPro BioTherapeutics NaPro BioTherapeutics, Inc., is a life
science company focused on the development of therapies for the
treatment of cancer and hereditary disease. Forward Looking
Statements The statements in this press release that are not
historical facts are forward-looking statements that represent
management's beliefs and assumptions as of the date hereof, based
on currently available information. Forward-looking statements can
be identified by the use of words such as "believes," "intends,"
"estimates," "may," "will," "should," "anticipates," "expected" or
comparable terminology or by discussions of strategy. Although the
Company believes that the expectations reflected in such
forward-looking statements are reasonable, it cannot assure that
these expectations will prove to be correct. Such statements
involve risks and uncertainties including those factors identified
under the captions "Risk Factors," "Special Note Regarding Forward
Looking Statements" or "Cautionary Note Regarding Forward Looking
Statements" in the Company's documents filed from time to time with
the SEC, including the Company's Current Report on Form 8-K/A,
dated February 11, 2004, and its Annual Report on Form 10-K for the
year ending December 31, 2003 filed with the SEC on March 11, 2004.
Should one or more of these risks materialize (or the consequences
of such a development worsen), or should the underlying assumptions
prove incorrect, actual results could differ materially from those
forecasted or expected. The Company disclaims any intention or
obligation to update publicly or revise such statements whether as
a result of new information, future events or otherwise. For
further information, please contact L. Robert Cohen, Vice
President, Investor Relations of NaPro BioTherapeutics, Inc.,
+1-212-218-8715. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT:
L. Robert Cohen of NaPro BioTherapeutics, Vice President, Investor
Relations, +1-212-218-8715; Investors, Lilian Stern of Stern
Investor Relations, Inc., +1-212-362-1200, or Media, Peter
Steinerman +1-516-374-3031, for NaPro BioTherapeutics Web site:
http://www.naprobio.com/
Copyright
Grafico Azioni Napro Biotherapeutics (NASDAQ:NPRO)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Napro Biotherapeutics (NASDAQ:NPRO)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Napro Biotherapeutics (MM) (NASDAQ): 0 articoli recenti
Più Napro Biotherapeutics (MM) Articoli Notizie